The Global Enteric Disease Testing Market size is expected to reach $4.6 billion by 2029, rising at a market growth of 3.2% CAGR during the forecast period.
Infections of the gastrointestinal tract, encompassing the small intestine, large intestine, and stomach, are known as enteric diseases. Bacteria, viruses, and parasites are just a few of the microorganisms that might cause these diseases. Salmonellosis, shigellosis, norovirus, rotavirus, amebiasis, cryptosporidiosis, and giardiasis are typical examples of enteric diseases. Others include cholera, Clostridium difficile (C. difficile), Escherichia coli (E. coli), shigellosis, and Helicobacter pylori (H. pylori).
To determine the exact pathogen triggering an enteric disease and to diagnose enteric diseases, numerous laboratory tests are employed. These tests often entail checking samples of blood, feces, or other fluids from the body for the presence of viruses, bacteria, and parasites known as enteric pathogens.
Enteric disorders are caused by bacterial, viral, and parasitic microorganisms that affect the intestines. Many of these illnesses can be spread from person to person and are typically brought on by consuming tainted food or drink. The symptoms of enteric infections include nausea, stomach pain, chills, fever, diarrhea, and loss of appetite.
One of the primary agents behind many water- and food-borne illnesses has been shown to be enteric bacteria. Diarrhea and hemolytic uremic syndrome (HUS) are becoming more common worldwide. Enteric bacterial infections are the most frequent cause. The enteric disease testing market is expected to expand throughout the forecast period due to factors such as rising rates of diarrhea, rising rates in emerging nations, higher government awareness, and various government and public sector initiatives.
The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Thermo Fisher Scientific, Inc. is the forerunner in the Enteric Disease Testing Market. Companies such as Neogen Corporation, Bureau Veritas S.A., and Eurofins Scientific SE are some of the key innovators in Enteric Disease Testing Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Thermo Fisher Scientific, Inc., SGS S.A., Eurofins Scientific SE, Bureau Veritas S.A., Intertek Group PLC, TÜV Nord Group, PerkinElmer, Inc., Becton, Dickinson and Company and Neogen Corporation.
Infections of the gastrointestinal tract, encompassing the small intestine, large intestine, and stomach, are known as enteric diseases. Bacteria, viruses, and parasites are just a few of the microorganisms that might cause these diseases. Salmonellosis, shigellosis, norovirus, rotavirus, amebiasis, cryptosporidiosis, and giardiasis are typical examples of enteric diseases. Others include cholera, Clostridium difficile (C. difficile), Escherichia coli (E. coli), shigellosis, and Helicobacter pylori (H. pylori).
To determine the exact pathogen triggering an enteric disease and to diagnose enteric diseases, numerous laboratory tests are employed. These tests often entail checking samples of blood, feces, or other fluids from the body for the presence of viruses, bacteria, and parasites known as enteric pathogens.
Enteric disorders are caused by bacterial, viral, and parasitic microorganisms that affect the intestines. Many of these illnesses can be spread from person to person and are typically brought on by consuming tainted food or drink. The symptoms of enteric infections include nausea, stomach pain, chills, fever, diarrhea, and loss of appetite.
One of the primary agents behind many water- and food-borne illnesses has been shown to be enteric bacteria. Diarrhea and hemolytic uremic syndrome (HUS) are becoming more common worldwide. Enteric bacterial infections are the most frequent cause. The enteric disease testing market is expected to expand throughout the forecast period due to factors such as rising rates of diarrhea, rising rates in emerging nations, higher government awareness, and various government and public sector initiatives.
COVID-19 Impact Analysis
COVID-19 testing and treatment took precedence over enteric illness testing as a result of the pandemic's impact on healthcare priorities. The COVID-19 pandemic required a massive redirection of resources towards COVID-19 testing, treatment, and vaccination efforts. This led to a diversion of resources away from other areas of healthcare, including enteric disease testing. This was due to a combination of factors, including reduced healthcare capacity, and social distancing measures. The COVID-19 pandemic disrupted many research projects related to enteric diseases, with resources and personnel being diverted towards COVID-19 research. The demand for enteric disease testing kits decreased during the pandemic, which negatively impacted market growth.Market Growth Factors
Increasing prevalence of enteric disease worldwide
The rise in the prevalence of several other enteric diseases such as clostridium difficile (C. difficile), shigellosis, Escherichia coli (E. coli), cholera, and salmonellosis - all of which can result in severe diarrhea or even death - also contributes to the increasing demand for these tests. Rising Millions of people contract enteric infections every year worldwide, but they are particularly prevalent in underdeveloped nations with subpar sanitation. Hence, the rising prevalence of enteric disease will propel the growth of the market throughout the forecast period.Rising number of technological breakthroughs owing to increased R&D
The demand for enteric disease testing may benefit from the growing technological developments and improvements in enteric disease testing equipment and methods. Testing efficiency gains, cost-effective testing, and quick test results may contribute to product development. Additionally, the healthcare business is embracing the growing trend of more efficient, effective, and affordable computing hardware connected to greater network connectivity, improved software, and advanced sensors. In light of this, the market may benefit financially from these variables in the years to come.Market Restraining Factors
High cost of testing and sampling
Automated enteric disease testing instruments are priced higher than their manual counterparts due to their advanced features and functions. The calculated cost of the media, instrument, and labor may be perceived as prohibitively expensive by certain end users. In addition, implementing numerous systems in testing laboratories has significantly increased the total capital cost investment. Utilizing molecular diagnostic techniques, particularly multiplexed assays, is a recent development in the healthcare industry compared to singleplex assays. However, the cost of multiplexed assay equipment is comparatively high, and the initial investment required for instrument installation is higher. This factor will impede the market's growth until cost-effective alternatives become available.Product Type Outlook
Based on product type, the enteric disease testing market is characterized into reagents & consumables and equipment. The equipment segment procured a considerable growth rate in the enteric disease testing market in 2022. Different types of enteric disease testing are used in the process, which is propelling the growth of the segment. Automated analyzers are used to perform rapid tests for enteric diseases. These tests can detect the presence of specific antigens or genetic material from the pathogen in a sample.
Technique Outlook
On the basis of technique, the enteric disease testing market is classified into molecular diagnostics and immunodiagnostics. The immunodiagnostics segment acquired the largest revenue share in the enteric disease testing market in 2022. Immunodiagnostic tests can provide results quickly, sometimes in as little as a few hours, which allows for earlier diagnosis and treatment of enteric diseases. Immunodiagnostic tests can detect even small amounts of pathogens or antibodies, making them highly sensitive and specific. This means they can accurately identify the presence of a specific pathogen and rule out other potential causes of the patient's symptoms.Disease Type Outlook
By disease type, the enteric disease testing market is divided into bacterial, viral, and parasitic. The high prevalence of bacterial enteric diseases such as salmonellosis, cholera, E. coli, and Helicobacter pylori, as well as the widespread utilization of enteric disease testing products for the diagnosis, are driving the growth of this market segment. In addition, due to increased knowledge of bacterial enteric disease diagnosis and a rising incidence of bacterial enteric diseases globally, the category is anticipated to experience rapid growth.End-user Outlook
Based on end user, the enteric disease testing market is segmented into academic & research institutes, hospital laboratories, and pharmaceutical & biotechnology companies. The academic & research institutes segment acquired a substantial revenue share in the enteric disease testing market in 2022. Academic and research institutes play a vital role in public health surveillance for enteric diseases. Testing and monitoring of enteric diseases in populations can help in identifying outbreaks, developing response plans, and implementing prevention and control strategies. Research institutes play a crucial role in identifying new pathogens responsible for enteric diseases.Regional Outlook
Region wise, the enteric disease testing market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment recorded the largest revenue share in the enteric disease testing market in 2022. The presence of a number of significant players as well as improvements in the manufacturing technology of enteric disease testing products in the region is what is driving the market's expansion. This is mostly due to an increase in the number of patients with enteric diseases, increased government support for research into the diagnosis of enteric diseases, and a sizable increase in capital income in industrialized nations.The Cardinal Matrix - Enteric Disease Testing Market Competition Analysis
The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Thermo Fisher Scientific, Inc. is the forerunner in the Enteric Disease Testing Market. Companies such as Neogen Corporation, Bureau Veritas S.A., and Eurofins Scientific SE are some of the key innovators in Enteric Disease Testing Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Thermo Fisher Scientific, Inc., SGS S.A., Eurofins Scientific SE, Bureau Veritas S.A., Intertek Group PLC, TÜV Nord Group, PerkinElmer, Inc., Becton, Dickinson and Company and Neogen Corporation.
Recent Strategies Deployed in Enteric Disease Testing Market
Partnerships, Collaborations and Agreements:
- Oct-2022: Thermo Fisher Scientific came into partnership with Genoox, a provider of fast and accurate tools to solve complex, genomic data challenges, delivering advanced, and end-to-end genomic analysis tools. The partnership aims to automate the interpretation and reporting of cytogenetic research data with AI. ChAS users can access Franklin, Genoox's cloud-based AI platform with the launch of CytoScan Automated Interpretation and Reporting (AIR) solution for making cytogenetic research data analysis easy.
- Apr-2022: SGS came into partnership with Liveome, a South Korea-based operator of microbiome research-based firm. The partnership focuses on the development and commercialization of LIV001, an inflammatory bowel disease (IBD) candidate. The partnership demonstrates SGS' ability to provide its services globally.
Product Launches and Product Expansions:
- Dec-2022: Thermo Fisher introduced TrueMark Infectious Disease Research Panels, developed to enable quick and precise detection and categorization for investigating microorganisms. The new panels are real-time polymerase chain reaction (PCR) syndromic panels and gives an option to the user to choose between standard or custom panels.
- Oct-2022: Thermo Fisher launched TaqPath Enteric Bacterial Select Panel, a CE-IVD marked test intended for common Gastrointestinal bacteria. The new test detects gastrointestinal (GI) bacteria and speeds up the root cause identification process. The GI bacteria detecting test is based on polymerase chain reaction (PCR) technology to examine the stool samples. The test can deliver results with 98% specificity, and sensitivity within two hours.
Mergers and Acquisitions:
- Jan-2023: Thermo Fisher Scientific Inc. took over The Binding Site Group, a global leader in specialty diagnostics. Through this acquisition, Thermo Fisher Scientific Inc. would be able to extend its current specialty diagnostics portfolio along with pioneering innovation in monitoring and diagnostics for numerous myelomas.
- Sep-2022: Bureau Veritas took over Galbraith Laboratories, a US-based operator of contract analytical testing. The addition of Galbraith expands the acquiring company's market presence in the personal care, industrial, and consumer healthcare markets, and further expands Bureau Veritas' market position in the North American region.
- Sep-2022: Neogen announced the completion of a merger with 3M's Food Safety business. 3M's food safety business is merged with Neogen. The combination expands the merged company's geographical footprint, digitization capabilities, etc.
- Jul-2022: Neogen completed the acquisition of Thai-Neo Biotech, a Thailand-based distributor of food safety products. The acquisition enables the acquiring company to establish a direct presence in Thailand and the Southeast Asian region. Further, the addition of Thai-Neo Biotech perfectly complements Neogen's operations in China, Australia, and India.
- Jun-2022: Eurofins acquired a majority stake in Ajal for Laboratories, a Saudi Arabia-based provider of laboratory services. This acquisition broadens the acquiring company's food and pharmaceutical product test offerings in Saudi Arabia. Further, the acquisition reflects Eurofins' commitment to developing a local and regional laboratory network across the whole Middle East.
- Sep-2021: Neogen acquired CAPInnoVet, a US-based provider of animal health medicines and products. This acquisition provides Neogen entry to the retail parasiticide market. The acquired company will be a part of Neogen's Animal Safety business segment.
- Apr-2021: Thermo Fisher Scientific Inc. took over PPD, Inc., a pharmaceutical company engaged in clinical research. Through this acquisition, the company would provide a vast range of services in the clinical development spectrum. This includes the development and manufacturing of the drug product, healthcare outcomes, trial logistics., scientific discovery, etc.
Scope of the Study
By End-user
- Hospital Laboratories
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
By Disease Type
- Bacterial
- Viral
- Parasitic
By Product Type
- Reagents & Consumables
- Equipment
By Technique
- Immunodiagnostics
- Molecular Diagnostics
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Merck KGaA
- Thermo Fisher Scientific, Inc.
- SGS S.A.
- Eurofins Scientific SE
- Bureau Veritas S.A.
- Intertek Group PLC
- TÜV Nord Group
- PerkinElmer, Inc.
- Becton, Dickinson and Company
- Neogen Corporation
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Global Enteric Disease Testing Market by End User
Chapter 5. Global Enteric Disease Testing Market by Disease Type
Chapter 6. Global Enteric Disease Testing Market by Product Type
Chapter 7. Global Enteric Disease Testing Market by Technique
Chapter 8. Global Enteric Disease Testing Market by Region
Chapter 9. Company Profiles
Companies Mentioned
- Merck KGaA
- Thermo Fisher Scientific, Inc.
- SGS S.A.
- Eurofins Scientific SE
- Bureau Veritas S.A.
- Intertek Group PLC
- TÜV Nord Group
- PerkinElmer, Inc.
- Becton, Dickinson and Company
- Neogen Corporation
Methodology
LOADING...
